The IL-23/Th 17 pathway in spondyloarthritis: The Royal Road?

被引：32
作者：
Wendling, Daniel [1 ]
Guillot, Xavier [1 ]
Prati, Clement [1 ]
机构：
[1] Univ Franche Comte, CHRU Besancon, Serv Rhumatol, F-25030 Besancon, France
来源：
JOINT BONE SPINE | 2015年 / 82卷 / 01期
关键词：
Spondyloarthritis; Interleukin-23; Interleukin-17; Pathophysiology; Treatment; ACTIVE PSORIATIC-ARTHRITIS; PROOF-OF-CONCEPT; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ANKYLOSING-SPONDYLITIS; USTEKINUMAB; INTERLEUKIN-17; MULTICENTER; EFFICACY; PHASE-3;
D O I：
10.1016/j.jbspin.2014.08.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 4
页数：4
相关论文
共 30 条
[11]   Interleukin-23: A central cytokine in the pathogenesis of spondylarthritis [J].
Gaston, J. S. Hill ;
Goodall, Jane C. ;
Baeten, Dominique .
ARTHRITIS AND RHEUMATISM, 2011, 63 (12) :3668-3671
[12]   Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats [J].
Glatigny, Simon ;
Fert, Ingrid ;
Blaton, Marie A. ;
Lories, Rik J. ;
Araujo, Luiza M. ;
Chiocchia, Gilles ;
Breban, Maxime .
ARTHRITIS AND RHEUMATISM, 2012, 64 (01) :110-120
[13]   Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells [J].
Jacques, Peggy ;
Lambrecht, Stijn ;
Verheugen, Eveline ;
Pauwels, Elin ;
Kollias, George ;
Armaka, Maria ;
Verhoye, Marleen ;
Van der Linden, Annemie ;
Achten, Rik ;
Lories, Rik J. ;
Elewaut, Dirk .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) :437-445
[14]   Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials [J].
Kavanaugh, Arthur ;
Ritchlin, Christopher ;
Rahman, Proton ;
Puig, Lluis ;
Gottlieb, Alice B. ;
Li, Shu ;
Wang, Yuhua ;
Noonan, Lenore ;
Brodmerkel, Carrie ;
Song, Michael ;
Mendelsohn, Alan M. ;
McInnes, Iain B. .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) :1000-1006
[15]   Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial [J].
McInnes, Iain B. ;
Sieper, Joachim ;
Braun, Juergen ;
Emery, Paul ;
van der Heijde, Desiree ;
Isaacs, John D. ;
Dahmen, Georg ;
Wollenhaupt, Juergen ;
Schulze-Koops, Hendrik ;
Kogan, Joseph ;
Ma, Shenglin ;
Schumacher, Martin M. ;
Bertolino, Arthur P. ;
Hueber, Wolfgang ;
Tak, Paul P. .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) :349-356
[16]   Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial [J].
McInnes, Iain B. ;
Kavanaugh, Arthur ;
Gottlieb, Alice B. ;
Puig, Lluis ;
Rahman, Proton ;
Ritchlin, Christopher ;
Brodmerkel, Carrie ;
Li, Shu ;
Wang, Yuhua ;
Mendelsohn, Alan M. ;
Doyle, Mittie K. .
LANCET, 2013, 382 (9894) :780-789
[17]   Mechanisms of Disease: Interleukin-17 and Type 17 Helper T Cells. [J].
Miossec, Pierre ;
Korn, Thomas ;
Kuchroo, Vijay K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (09) :888-898
[18]   Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS) [J].
Poddubnyy, Denis ;
Hermann, Kay-Geert A. ;
Callhoff, Johanna ;
Listing, Joachim ;
Sieper, Joachim .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (05) :817-823
[19]   Active immunization against IL-23p19 improves experimental arthritis [J].
Ratsimandresy, Rojo Anthony ;
Duvallet, Emilie ;
Assier, Eric ;
Semerano, Luca ;
Delavallee, Laure ;
Bessis, Natacha ;
Zagury, Jean-Francois ;
Boissier, Marie-Christophe .
VACCINE, 2011, 29 (50) :9329-9336
[20]   Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial [J].
Ritchlin, Christopher ;
Rahman, Proton ;
Kavanaugh, Arthur ;
McInnes, Iain B. ;
Puig, Lluis ;
Li, Shu ;
Wang, Yuhua ;
Shen, Yaung-Kaung ;
Doyle, Mittie K. ;
Mendelsohn, Alan M. ;
Gottlieb, Alice B. .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) :990-999
123